Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

Vertex Pharmaceuticals (VRTX) reported $2.96 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 12.1%. EPS of $4.52 for the same period compares to -$12.83 a ...

Johnson & Johnson Vision professional affairs consultant, Nadia Siddiqi, outlines key considerations for locums when fitting ...

Google DeepMind CEO Demis Hassabis heads Gemini and the company's AI push while gaining more power. Here's how he became ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

Zepbound is a prescription drug used for weight loss and weight management in adults. Learn about the drug's dosage, form, strengths, how to use, and more.

AI for enterprise is already here, helping companies streamline their operations, serve their customers better, and save ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...